ProQR dosed first participant in Phase 1 AX-0811 study
ProQR Therapeutics N.V. announced the first participant was dosed in its Phase 1 study of AX-0811, alongside a Virtual Investor and Analyst Educational Event scheduled for September 30, 2026.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.